October 21, 2019
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer meets primary and secondary endpoints
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.